Drugs / RBV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01756079 Background | Feb 2013 → Nov 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01756079 ↗ |
| Route | Oral | “RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses)” NCT01756079 ↗ |